Board of Directors

Ann-Charlotte Rosendahl

Chairman of the Board

Ann-Charlotte Rosendahl, born in 1963, is a board member of Toleranzia since 2020. Rosendahl has a B.Sc. in Business Administration from the Lund University and has over 20 years of experience in the development, commercialization and launch of drugs on the international stage. She has held senior positions withinin MSD, AstraZeneca and Roche, and has lived and worked in the United States and Switzerland for a number of years. She also has experience of strategic and operational work in biotech, as well as business development and board work. Holdings as of September 30, 2024: 87 520 shares (personal ownership). Independent in relation to both the company and its management as well as to major shareholders.

Thomas Eldered

Board member

Thomas Eldered, born in 1960, is a board member of Toleranzia since 2021. Eldered holds a MSc in Industrial Engineering and Management from Linköping University, Sweden. He co-founded Recipharm in 1995, led the IPO in 2014 and stayed with the company until early 2021 when it was taken private again. Under his leadership, the organization grew to approximately 9000 employees at 30 facilities located in ten countries, offering pharmaceutical companies full service from early development to commercial production. He is executive chairman of Flerie AB (publ) and board member or chairman of the board in several of Flerie Invest’s portfolio companies. Holdings as of September 30, 2024: 114 401 382 shares (via related party). Dependent in relation to both the company and its management as well as to major shareholders.

Maarten Kraan

Board member

Maarten Kraan, born in 1961, is a board member of Toleranzia since 2018. He has a medical degree since 1991, board certification Rheumatology in 1998, and PhD in Immunology in 2000, all from Leiden university and has conducted many clinical trials with many successful drugs. Kraan began in the pharmaceutical industry in 2003 and has worked in several companies; Schering-Plow, Bristol-Myers-Squibb, Roche-Genentech, AstraZeneca, Therachon, Stallergenes-Greer, Pierre-Fabre, AM-Pharma and Citryll. He has had different positions in research, clinical development, and medical affairs. He has published a series of articles on translational medicine and was adjunct professor of rheumatology at the Sahlgrenska Academy of Gothenburg University. Holdings as of September 30, 2024: 407 142 shares (personal ownership). Independent in relation to both the company and its management as well as to major shareholders.

Eva Lindgren

Board member

Eva Lindgren, born in 1950, is a board member of Toleranzia since 2018. Lindgren has an MBA with a focus on international marketing and a B.Sc. with a focus on urban planning from the University of Gothenburg, and has 40 years of experience from AstraZeneca through senior positions, including responsibility for two pharmaceutical projects that led to market, but also in business management, international marketing and public-private partnership between pharmaceutical companies and the European Commission. Board member of the Kulturtubskoncernen, AB Gypius, and RolfAllan Design AB. Holdings as of September 30, 2024: 61 736 shares (personal ownership). Independent in relation to both the company and its management as well as to major shareholders.

Jan Mattsson

Board member

Jan Mattsson, born in 1964, is a board member of Toleranzia since 2020. Mattsson has a Ph.D. in Biochemistry from Chalmers University of Technology & Gotheburg University and has more than 30 years of experience in the pharmaceutical industry. Jan is one of the founders of Albireo Pharma, an American NASDAQ listed company focused on orphan liver diseases. Jan was Chief Scientific Officer and Managing Director (Albireo AB). The company was sold to Ipsen in 2023. Before he started Albireo in 2008, he held various leading positions in research and development at AstraZeneca. Jan has experience of research & development during all phases of drug development in a number of therapy areas but also in international business & corporate development. Holdings as of September 30, 2024: 20 644 shares (personal ownership). Independent in relation to both the company and its management as well as to major shareholders.

Kristian Sandberg

Board member

Kristian Sandberg, born in 1961, is a board member of Toleranzia since 2017. Sandberg has a PhD and Associate Professor degree in Immunology from the Swedish University of Agricultural Sciences and is an experienced leader in the pharmaceutical industry's research and development. Sandberg has been working at AstraZeneca for over 20 years in various functions, primarily with project management. He has experience in the development of both protein and conventional small molecule based drugs from concept to clinical Phase II studies, both in the field of neuroscience therapy and respiratory, inflammatory and autoimmune diseases. Sandberg is also active as a researcher at Karolinska Institutet and has had various assignments within the Foundation for Strategic Research. Since 2015, Sandberg is running the business at SciLifeLab's pharmaceutical platform at Uppsala University, whose mission is to support pharmaceutical research in Sweden. Holdings as of September 30, 2024: 232 142 shares (personal ownership). Independent in relation to both the company and its management as well as to major shareholders.